Brief: PTC To Expand Rare Disease Portfolio With Acquisition Of BLA-Stage St-920 Fabry Disease Program
12/08/2026 22:14
BRIEF-PTC To Expand Rare Disease Portfolio With Acquisition Of BLA-Stage St-920 Fabry Disease Program Aug 12 (Reuters) - PTC Therapeutics, Inc. PTCT.O:
PTC TO EXPAND RARE DISEASE PORTFOLIO WITH ACQUISITION OF BLA-STAGE ST-920 FABRY DISEASE PROGRAM
PTC THERAPEUTICS, - TO BUY ST-920 GENE THERAPY FOR FABRY DISEASE FROM SANGAMO
PTC THERAPEUTICS, - DEAL TERMS INCLUDE $111 MILLION UPFRONT AND UP TO $100 MILLION IN MILESTONE PAYMENTS
PTC THERAPEUTICS, - ROLLING BLA SUBMISSION FOR ST-920 EXPECTED TO COMPLETE IN Q4 2026
Source text: ID:nPn7MNr1Sa
Further company coverage: PTCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PTC Therapeutics
See all newsBrief: PTC Completes Acquisition Of St-920 Fabry Disease Gene Therapy
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: PTC To Expand Rare Disease Portfolio With Acquisition Of BLA-Stage St-920 Fabry Disease Program
PTC Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
PTC Therapeutics Q2 revenue more than doubles, raises 2026 outlook